



**SERES**  
THERAPEUTICS™

## Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2022-- [Seres Therapeutics, Inc.](#) (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:15 a.m. ET.

A live audio webcast of the presentation will be available under the "Investors and News" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for approximately 21 days.

### About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent *C. difficile* infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220104005194/en/): <https://www.businesswire.com/news/home/20220104005194/en/>

### PR

Kristin Ainsworth  
[kainsworth@serestherapeutics.com](mailto:kainsworth@serestherapeutics.com)

### IR

Carlo Tanzi, Ph.D.  
[ctanzi@serestherapeutics.com](mailto:ctanzi@serestherapeutics.com)

Source: Seres Therapeutics, Inc.